Interleukin 1 beta inhibitors - Pipeline Insight, 2024

This “Interleukin 1 Beta Inhibitors - Pipeline Insight, 2024” report provides comprehensive insights about 11+ companies and 12+ pipeline drugs in Interleukin 1 Beta Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Interleukin 1 Beta Inhibitors Understanding

Interleukin 1 Beta Inhibitors: Overview

Interleukin 1 Beta Inhibitors is a potent pro-inflammatory cytokine produced by cells of the innate immune system. Interleukin 1 beta (IL-1ß) is produced as an inactive 31 kDa precursor, termed pro-IL-1ß, in response to molecular motifs carried by pathogens called ‘pathogen associated molecular patterns’ (PAMPs). It is a major cytokine involved in monocyte activation and activation of proinflammatory signaling pathways in peripheral tissues and brain. IL-1ß expression and its secretion are tightly regulated. IL-1ß is a master regulator of inflammation via controlling a variety of innate immune processes. IL-1 has a wide range of biological functions, which include acting as a leukocytic pyrogen, a mediator of fever and a leukocytic endogenous mediator, and an inducer of several components of the acute-phase response and lymphocyte-activating factor (LAF). The blocking of IL-1 could be effective strategies for the management of classic autoimmune diseases and autoinflammatory diseases.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Interleukin 1 Beta Inhibitors R&D. The therapies under development are focused on novel approaches for Interleukin 1 Beta Inhibitors.

Interleukin 1 Beta Inhibitors Emerging Drugs Chapters

This segment of the Interleukin 1 Beta Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Interleukin 1 Beta Inhibitors Emerging Drugs

Gevokizumab: Novartis Gevokizumab (VPM087) is a novel, human-engineered monoclonal anti - IL-1ß antibody. Gevokizumab binds strongly to interleukin-1 beta (IL-1 beta), a pro-inflammatory cytokine. The drug is in Phase I clinical studies for the treatment of patients with metastatic colorectal cancer, metastatic gastroesophageal cancer and metastatic renal cellcarcinoma.

Goflikicept: TRPHARMGoflikicept (RPH-104) is a heterodimeric fusion protein containing IL-1R1 and IL-1RAcP linked to immunoglobulin heavy chains and is highly selectively binds IL-1ß. TRPHARM is evaluating Goflikicept in Phase II/III clinical studies for the treatment of Pericarditis and in Phase II clinical studies for Gout Attack and myocardial infarction.

Interleukin 1 Beta Inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different Interleukin 1 Beta Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Interleukin 1 Beta Inhibitors

There are approx. 11+ key companies which are developing the Interleukin 1 Beta Inhibitors. The companies which have their Interleukin 1 Beta Inhibitors drug candidates in the most advanced stage, i.e. Phase II/III include, TRPHARM.

Phases

This report covers around 12+ products under different phases of clinical development like

• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Interleukin 1 Beta Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Interleukin 1 Beta Inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Interleukin 1 Beta Inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Interleukin 1 Beta Inhibitors drugs.

Interleukin 1 Beta Inhibitors Report Insights

• Interleukin 1 Beta Inhibitors Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Interleukin 1 Beta Inhibitors Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing Interleukin 1 Beta Inhibitors drugs?
• How many Interleukin 1 Beta Inhibitors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for Interleukin 1 Beta Inhibitors?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Interleukin 1 Beta Inhibitors therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Interleukin 1 Beta Inhibitors and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Novartis
• Regeneron Pharmaceuticals
• TRPHARM
• Hutchison MediPharma
• Tetra Bio Pharma
• Jiangsu T-mab BioPharma
• Flame Biosciences

Key Products

• Canakinumab
• Rilonacept
• Gevokizumab
• Goflikicept
• HMPL-004
• HU 308
• TK 002
• FL-101 Flame Biosciences

This product will be delivered within 2 business days.